Arbutus Biopharma Corporation ABUS Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $14.08M+128% | $6.17M-66.0% | $18.14M-53.5% | $39.02M+255% | ||
| $25.24M-53.3% | $54.04M-26.7% | $73.7M-12.7% | $84.41M+28.9% | ||
| $15.89M-28.1% | $22.11M-1.6% | $22.48M+26.0% | $17.83M+4.1% | ||
| $52.24M-36.7% | $82.49M-14.3% | $96.24M-7.9% | $104.48M+23.6% | ||
| -$38.16M+50.0% | -$76.32M+2.3% | -$78.1M-19.3% | -$65.46M+11.0% | ||
| -271%+966pp | -1,236.7%-806pp | -430.5%-263pp | -167.8%+501pp | ||
| $97K-29.2% | $137K-70.2% | $459K-73.4% | $1.73M-39.6% | ||
| $4.66M-27.2% | $6.4M+21.8% | $5.25M+1,083% | $444K+116% | ||
| -$33.5M+52.1% | -$69.92M+4.0% | -$72.85M-4.9% | -$69.46M+8.9% | ||
| -237.9%+895pp | -1,133%-731pp | -401.6%-224pp | -178%+516pp | ||
| -$0.17+55.3% | -$0.38+13.6% | -$0.44+6.4% | -$0.47+43.4% | ||
| -$37.72M+49.7% | -$74.93M+2.3% | -$76.71M-19.9% | -$63.98M+10.8% | ||
| -267.8%+946pp | -1,214.2%-791pp | -422.8%-259pp | -164%+489pp | ||
| -$38.16M+50.0% | -$76.32M+2.3% | -$78.1M-19.3% | -$65.46M+11.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Arbutus Biopharma Corporation's revenue?
- Arbutus Biopharma Corporation (ABUS) generated $191.4M in revenue over the trailing twelve months, up 2889.9% year over year.
- Is Arbutus Biopharma Corporation profitable?
- Arbutus Biopharma Corporation reported $160.7M in net income over the trailing twelve months, a 84.0% net margin.
- What is Arbutus Biopharma Corporation's earnings per share?
- Arbutus Biopharma Corporation's diluted EPS over the trailing twelve months is $0.83.
- Where does Arbutus Biopharma Corporation's income statement data come from?
- Every line is extracted from Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
